旗濱集團(601636.SH):中性硼硅藥用玻璃項目自2021年4月底進入調試階段
格隆匯8月20日丨旗濱集團(601636.SH)發佈股價異常波動公吿,公司新建的5條光伏玻璃生產線處於籌建或建設中,預計上述項目2021年內均不能完成項目建設;公司中性硼硅藥用玻璃項目自2021年4月底進入調試階段,目前仍處於摸索不同產品的工藝技術參數的過程中,尚無產品投放市場。公司以上項目均處於發展初期階段,受未來行業政策調整以及市場因素影響較大,實現預期盈利水平尚存在諸多不確定因素。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.